vs
Boot Barn Holdings, Inc.（BOOT）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Boot Barn Holdings, Inc.的1.1倍（$772.1M vs $705.6M），Revvity净利率更高（12.7% vs 12.2%，领先0.6%），Boot Barn Holdings, Inc.同比增速更快（16.0% vs 5.9%），Revvity自由现金流更多（$161.8M vs $148.0M），过去两年Boot Barn Holdings, Inc.的营收复合增速更高（34.8% vs 9.0%）
Henry Boot plc是总部位于英国谢菲尔德的地产开发企业，1919年于伦敦证券交易所上市，是英国首家上市的住宅建造商。两次世界大战期间，该公司住宅建造量位居全英首位，目前仍是英国颇具规模的建筑与物业管理服务商。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
BOOT vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.1倍
$705.6M
营收增速更快
BOOT
高出10.2%
5.9%
净利率更高
RVTY
高出0.6%
12.2%
自由现金流更多
RVTY
多$13.8M
$148.0M
两年增速更快
BOOT
近两年复合增速
9.0%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $705.6M | $772.1M |
| 净利润 | $85.8M | $98.4M |
| 毛利率 | 39.9% | — |
| 营业利润率 | 16.3% | 14.5% |
| 净利率 | 12.2% | 12.7% |
| 营收同比 | 16.0% | 5.9% |
| 净利润同比 | 14.3% | 3.9% |
| 每股收益（稀释后） | $2.79 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BOOTRVTY
| Q4 25 | $705.6M | $772.1M | ||
| Q3 25 | $505.4M | $698.9M | ||
| Q2 25 | $504.1M | $720.3M | ||
| Q1 25 | $453.7M | $664.8M | ||
| Q4 24 | $608.2M | $729.4M | ||
| Q3 24 | $425.8M | $684.0M | ||
| Q2 24 | $423.4M | $691.7M | ||
| Q1 24 | $388.5M | $649.9M |
净利润BOOTRVTY
| Q4 25 | $85.8M | $98.4M | ||
| Q3 25 | $42.2M | $46.7M | ||
| Q2 25 | $53.4M | $53.9M | ||
| Q1 25 | $37.5M | $42.2M | ||
| Q4 24 | $75.1M | $94.6M | ||
| Q3 24 | $29.4M | $94.4M | ||
| Q2 24 | $38.9M | $55.4M | ||
| Q1 24 | $29.4M | $26.0M |
毛利率BOOTRVTY
| Q4 25 | 39.9% | — | ||
| Q3 25 | 36.4% | 53.6% | ||
| Q2 25 | 39.1% | 54.5% | ||
| Q1 25 | 37.1% | 56.5% | ||
| Q4 24 | 39.3% | — | ||
| Q3 24 | 35.9% | 56.3% | ||
| Q2 24 | 37.0% | 55.7% | ||
| Q1 24 | 35.9% | 54.6% |
营业利润率BOOTRVTY
| Q4 25 | 16.3% | 14.5% | ||
| Q3 25 | 11.2% | 11.7% | ||
| Q2 25 | 14.0% | 12.6% | ||
| Q1 25 | 11.0% | 10.9% | ||
| Q4 24 | 16.4% | 16.3% | ||
| Q3 24 | 9.4% | 14.3% | ||
| Q2 24 | 11.9% | 12.4% | ||
| Q1 24 | 9.8% | 6.8% |
净利率BOOTRVTY
| Q4 25 | 12.2% | 12.7% | ||
| Q3 25 | 8.4% | 6.7% | ||
| Q2 25 | 10.6% | 7.5% | ||
| Q1 25 | 8.3% | 6.4% | ||
| Q4 24 | 12.3% | 13.0% | ||
| Q3 24 | 6.9% | 13.8% | ||
| Q2 24 | 9.2% | 8.0% | ||
| Q1 24 | 7.6% | 4.0% |
每股收益（稀释后）BOOTRVTY
| Q4 25 | $2.79 | $0.86 | ||
| Q3 25 | $1.37 | $0.40 | ||
| Q2 25 | $1.74 | $0.46 | ||
| Q1 25 | $1.24 | $0.35 | ||
| Q4 24 | $2.43 | $0.77 | ||
| Q3 24 | $0.95 | $0.77 | ||
| Q2 24 | $1.26 | $0.45 | ||
| Q1 24 | $0.96 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $200.1M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.3B | $7.3B |
| 总资产 | $2.4B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BOOTRVTY
| Q4 25 | $200.1M | $919.9M | ||
| Q3 25 | $64.7M | $931.4M | ||
| Q2 25 | $95.3M | $991.8M | ||
| Q1 25 | $69.8M | $1.1B | ||
| Q4 24 | $152.9M | $1.2B | ||
| Q3 24 | $37.4M | $1.2B | ||
| Q2 24 | $83.4M | $2.0B | ||
| Q1 24 | $75.8M | $1.7B |
股东权益BOOTRVTY
| Q4 25 | $1.3B | $7.3B | ||
| Q3 25 | $1.2B | $7.4B | ||
| Q2 25 | $1.2B | $7.6B | ||
| Q1 25 | $1.1B | $7.6B | ||
| Q4 24 | $1.1B | $7.7B | ||
| Q3 24 | $1.0B | $7.9B | ||
| Q2 24 | $981.8M | $7.9B | ||
| Q1 24 | $943.6M | $7.8B |
总资产BOOTRVTY
| Q4 25 | $2.4B | $12.2B | ||
| Q3 25 | $2.3B | $12.1B | ||
| Q2 25 | $2.1B | $12.4B | ||
| Q1 25 | $2.0B | $12.4B | ||
| Q4 24 | $2.0B | $12.4B | ||
| Q3 24 | $1.9B | $12.8B | ||
| Q2 24 | $1.8B | $13.4B | ||
| Q1 24 | $1.7B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $209.7M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $148.0M | $161.8M |
| 自由现金流率自由现金流/营收 | 21.0% | 21.0% |
| 资本支出强度资本支出/营收 | 8.7% | 2.6% |
| 现金转化率经营现金流/净利润 | 2.44× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $89.8M | $509.4M |
8季度趋势，按日历期对齐
经营现金流BOOTRVTY
| Q4 25 | $209.7M | $182.0M | ||
| Q3 25 | $25.7M | $138.5M | ||
| Q2 25 | $73.8M | $134.3M | ||
| Q1 25 | $-43.1M | $128.2M | ||
| Q4 24 | $157.1M | $174.2M | ||
| Q3 24 | $-7.8M | $147.9M | ||
| Q2 24 | $41.3M | $158.6M | ||
| Q1 24 | — | $147.6M |
自由现金流BOOTRVTY
| Q4 25 | $148.0M | $161.8M | ||
| Q3 25 | $-17.5M | $120.0M | ||
| Q2 25 | $42.4M | $115.5M | ||
| Q1 25 | $-83.1M | $112.2M | ||
| Q4 24 | $114.2M | $149.8M | ||
| Q3 24 | $-46.1M | $125.6M | ||
| Q2 24 | $14.2M | $136.6M | ||
| Q1 24 | — | $129.7M |
自由现金流率BOOTRVTY
| Q4 25 | 21.0% | 21.0% | ||
| Q3 25 | -3.5% | 17.2% | ||
| Q2 25 | 8.4% | 16.0% | ||
| Q1 25 | -18.3% | 16.9% | ||
| Q4 24 | 18.8% | 20.5% | ||
| Q3 24 | -10.8% | 18.4% | ||
| Q2 24 | 3.4% | 19.7% | ||
| Q1 24 | — | 20.0% |
资本支出强度BOOTRVTY
| Q4 25 | 8.7% | 2.6% | ||
| Q3 25 | 8.6% | 2.6% | ||
| Q2 25 | 6.2% | 2.6% | ||
| Q1 25 | 8.8% | 2.4% | ||
| Q4 24 | 7.1% | 3.4% | ||
| Q3 24 | 9.0% | 3.3% | ||
| Q2 24 | 6.4% | 3.2% | ||
| Q1 24 | — | 2.7% |
现金转化率BOOTRVTY
| Q4 25 | 2.44× | 1.85× | ||
| Q3 25 | 0.61× | 2.97× | ||
| Q2 25 | 1.38× | 2.49× | ||
| Q1 25 | -1.15× | 3.03× | ||
| Q4 24 | 2.09× | 1.84× | ||
| Q3 24 | -0.26× | 1.57× | ||
| Q2 24 | 1.06× | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BOOT
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
